Fundamentals of Liver Disease- Hepatitis B

4.85 (13 votes)

There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

 

The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

Key topic areas:

HBV: Epidemiology and Screening
Patient with positive Hepatitis B serologies
Natural history of HBV and identification of treatment candidates
Management of the Chronic HBV patient with co-morbid and other conditions
Antiviral treatment of the Patient with Chronic HBV
Prevention of HBV infection
Hepatitis B in the Pediatric Patient

COMPONENTS
Online:
7 online interactive, narrated modules 30 to 40 minutes in length
Pre- and post-test questions for each module

Original release date: April 10, 2014
Review date: July 1, 2017
Re-release date: December 1, 2017
Expiration date: November 30, 2019
Time to complete each module: 45-60 minutes


Copyright:
All faculty in this activity have given their permission for publication OR
©2017 AASLD

Contact Information
For questions on CE credit for this activity contact Certificate@AmedcoEmail.com
For questions on MOC/CME/CE content or the activity web site, contact education@aasld.org.

Marc G. Ghany

Dr. Ghany is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

 

Tram T. Tran

Dr. Tran is Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

Norah A. Terrault

Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

 

 

Marion G. Peters

Anna S. Lok

Brian J. McMahon

Maureen M. Jonas

Key:

Complete
Failed
Available
Locked
Module 1: HBV: Epidemiology and Screening
Module 1 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 1: HBV: Epidemiology and Screening
Open to view video.
Open to view video. Marc Ghany
Module 1 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 1 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 1 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 1 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 1 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 2: Patient with Positive Hepatitis B Serologies
Module 2 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 2: Patient with Positive Hepatitis B Serologies
Open to view video.
Open to view video. Tram Tran
Module 2 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 2 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 2 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 2 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 2 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 3: Natural History of HBV and Identification of Treatment Candidates
Module 3 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 3- Natural History of HBV and Identification of Treatment Candidates
Open to view video.
Open to view video. Dr. Norah Terrault
Module 3 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 3 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 3 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 3 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 3 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 4: Management of the Chronic HBV Patient with Co-Morbid and Other Conditions
Module 4 Pre-Test
4 Questions  |  1 attempt  |  3/4 points to pass
4 Questions  |  1 attempt  |  3/4 points to pass
Module 4: Management of the Chronic HBV Patient with Co-Morbid and Other Conditions
Open to view video.
Open to view video. Dr. Marion Peters
Module 4 Post-Test
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
Module 4 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 4 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 4 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 4 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 5: Antiviral Treatment of the Patient with Chronic HBV
Module 5 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 5: Antiviral Treatment of the Patient with Chronic HBV
Open to view video.
Open to view video.
Module 5 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 5 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 5 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 5 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 5 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 6: Prevention of HBV Infection
Module 6 Pre-Test
4 Questions  |  1 attempt  |  3/4 points to pass
4 Questions  |  1 attempt  |  3/4 points to pass
Module 6: Prevention of HBV Infection
Open to view video.
Open to view video. Brian McMahon
Module 6 Post-Test
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
Module 6 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 6 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 6 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 6 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Module 7: Hepatitis B in the Pediatric Patient
Module 7 Pre-Test
5 Questions  |  1 attempt  |  3/5 points to pass
5 Questions  |  1 attempt  |  3/5 points to pass
Module 7: Hepatitis B in the Pediatric Patient
Open to view video.
Open to view video. Maureen Jonas
Module 7 Post-Test
5 Questions  |  Unlimited attempts  |  3/5 points to pass
5 Questions  |  Unlimited attempts  |  3/5 points to pass
Module 7 CE Credits
0.50 CE Credits credits  |  Certificate available
0.50 CE Credits credits  |  Certificate available
Module 7 CME Credits
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
Module 7 MOC Points
Up to 0.50 medical credits available  |  Certificate available
Up to 0.50 medical credits available  |  Certificate available
Module 7 Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.

Learning Objective:
• Identify patients with liver disease
• Apply diagnostic tests appropriately
• Discuss important counseling
• Recognize treatment/referral priorities
• Identify first line therapies for different liver diseases
• Refer to specialist in a timely and appropriate fashion

This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

CME

Accreditation Statement

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

AASLD designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse

Amedco is accredited as a provider of continuin nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and AASLD. Maximum of 3.5 contact hours.

Maintenance of Certification (MOC) Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

How to Earn/Claim MOC

 

•    For each module that you wish to claim MOC points for you must:

 

            o    Complete the pre-test

 

            o    Review/watch the slides in the presentation

 

            o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

 

            o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

 

•    AASLD submits MOC points on behalf of its learners to ABIM once a month between 15th-20th. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

 

•    MOC points are available for ABIM board certified physicians only.

DISCLOSURE OF CONFLICTS OF INTEREST

AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
The organizers and faculty have reported the following disclosures:

Marc Ghany, MD
Faculty
Nothing to disclose

Tram Tran, MD
Faculty
Grant/Research Support: Bristol-Myers Squibb, Gilead; Consulting: Bristol-Myers Squibb, Gilead
Advisory Committee or Review Panels: Bristol-Myers Squibb, Gilead

Marion Peters, MD
Faculty
Employment (Spouse): Genentech Research and Development (subsidiary of Roche)

Anna S.F. Lok, MD
Faculty
Grant/Research Support: BMS and Gilead

Brian McMahon, MD, FAASLD
Faculty
Grant/Research Support:  Gilead Sciences- grant received by department at institution and not directly.

Maureen Jonas, MD
FacultyAdvisory Committee or Review Panels: Served as chair of DSMB for Gilead
Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Roche, Echosens (equipment only)
Consulting: AbbVie

Lauren Beste, MD
Organizer
Nothing to disclose

Michael Fried, MD, FAASLD
Organizer, Faculty
Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and NIH
Scientific Consultant: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and TARGET PharmaSolutions

Guadalupe Garcia-Tsao, MD
Organizer
Advisory Committee: Abbvie, Fibrogen

Leslie Hayes, MD
Organizer
Nothing to disclose

Patrick Horne, MSN, ARNP, FNP-BC
Organizer
Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie

Rennie Mills, PA-C
Organizer
Advisory Board: Gilead

Minhhuyen Nguyen, MD
Organizer
Nothing to disclose

Norah Terrault, MD
Organizer, Faculty
Consulting: Dynavax Technologies, Novartis Pharmaceuticals, Echosens North America Inc
Continuing Medical Education: Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc 
Educational Material Development: CCO Hepatitis

John Ward, MD
Organizer
Nothing to disclose

Stephanie Graham, MA
AASLD Staff
Nothing to disclose

Claudia Ventura
AASLD Staff
Nothing to disclose

Online Learning Committee

Calvin Q. Pan, MD, MACP, FAASLD
Reviewer
Advisory Board: BMS, Gilead, Abbvie Grants/Research Support:  Gilead, Merck  Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy

Lopa Mishra, MD, FAASLD
Reviewer
Nothing to Disclose

Gene Y Im, MD
Reviewer
Nothing to Disclose

Iris W Liou, MD
Reviewer
Nothing to Disclose

Jesse M Civan, MD
Reviewer
Education: Merck

HoChong Gilles, FNP
Reviewer
Nothing to Disclose

Julius Wilder, MD, PhD
Reviewer
Nothing to Disclose

Nicolas M Intagliata, MD
Reviewer
Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical

Andrew S. deLemos, MD
Reviewer
Consulting: Novartis

Samar H. Ibrahim, MBCHB
Reviewer
Nothing to Disclose

This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Acknowledgement of Commercial Support:
No commercial support was received for this enduring material activity.